Form 8-K - Current report:
SEC Accession No. 0001193125-22-087458
Filing Date
2022-03-29
Accepted
2022-03-29 08:06:02
Documents
14
Period of Report
2022-03-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d344096d8k.htm   iXBRL 8-K 33830
2 EX-10.1 d344096dex101.htm EX-10.1 54242
3 EX-10.2 d344096dex102.htm EX-10.2 96321
  Complete submission text file 0001193125-22-087458.txt   350297

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kpti-20220328.xsd EX-101.SCH 2854
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20220328_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20220328_pre.xml EX-101.PRE 11260
8 EXTRACTED XBRL INSTANCE DOCUMENT d344096d8k_htm.xml XML 3342
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 22777476
SIC: 2834 Pharmaceutical Preparations